Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

PolyPid Ltd.80 enrolled

Overview

This study is aimed to assess the anti-infective efficacy of D-PLEX over a period of 3 months post operation as well as the safety over a period of 6 months, by preventing sternal infection post cardiac surgery in patients above the age of 18, including high risk patients for infection. This study is a 2 parts study: part 1 is a single arm, part 2 is randomized controlled study.

D-PLEX is a new formulation of extended controlled release Doxycycline. Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care. D-PLEX will be administered as a single application during a cardiac surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care. The study will assess the efficacy and safety of the controlled release antibiotic (doxycycline) by the reduction in the number of sternal infections observed during the treatment period in any subject above the age of 18 years, including patients with high risk for infection. Additional follow up for prolonged safety assessments only, will be done as follows until 24 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Postoperative Wound Infection Superficial Incisional Postoperative Wound Infection Deep Incisional Surgical Site

Interventions

D-PLEXDRUG

D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.

Open heart surgeryPROCEDURE

Subject will undergo open heart surgery according to standard of care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or non-pregnant female above 18 years old 2. Female of childbearing potential should have a negative serum pregnancy test prior to index procedure. Note: All female of childbearing potential must agree to use a highly effective method of contraception (such as double barrier, oral or parenteral hormonal, intrauterine device and spermicide) consistently and correctly for the duration of the study. 3. Subjects undergoing elective or urgent cardiac surgery, who are preoperative stable hemodynamically. 4. Subjects with (20≤BMI≤40) 5. Subjects who sign a written informed consent. Exclusion Criteria: 1. Received any investigational drug within 30 days of start of study or within 5½ half-lives (pharmacokinetic or pharmacodynamics) prior to enrollment (whichever is longer). 2. Are ineligible to receive treatment with: * Any preoperative active significant infection * Antibiotic sensitivity to Doxycycline and/or tetracycline family of drugs * Known allergies to more than 3 substances.(Patients should fill the allergy questioners during the enrolment process) * History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with intra-venous steroids/epinephrine or in the opinion of the investigator the patient is at high risk of developing severe allergic / hypersensitivity reactions. * History of uncontrolled Asthma (GINA III-IV) * History of chronic urticaria 3. Pregnant or breastfeeding women. 4. Subjects who have taken oral or IV doxycycline during the last 4 weeks prior to screening. 5. Subjects who undergo cardiac/open chest surgeries, which are classified as emergency. 6. Immunocompromised subjects from any reason, at screening. 7. Subjects that undergone TIA/ CVA within the last 3 months prior to enrollment. 8. Subjects that previously underwent any cardiac surgery through mid-sternum. 9. In the opinion of investigator, subject is not eligible to participate in the study due to a cognitive status, medical condition or medication status (other than items listed above)

Locations (5)

Soroka Medical Center

Beersheba, Israel

Rambam Medical Center

Haifa, Israel

Assuta Medical Center

Tel Aviv, Israel

Sheba Medical Center

Tel Litwinsky, Israel

Poriya Medical Center

Tiberias, Israel

Outcomes

Primary Outcomes

Sternal Infection identified within 90 days post-cardiac surgery. Primary sternal infection as measured by the proportion of subjects with at least 1 identified primary sternal infection within 90 days post-cardiac surgery.

Decrease of infection rate as measured by the proportion of subjects with at least 1 identified sternal infection within 90 days post-cardiac surgery.

Time frame: Within 90 days post-cardiac surgery.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.